Coca-Cola Europacific Partners (CCEP) is an entrenched, high-quality bottler generating roughly $2 billion in annual free cash flow. While it operates with structurally lower margins than franchisors like KO, its local monopoly on distribution and vast scale provide a wide economic moat. It is a predictable compounder actively returning capital through dividends and buybacks. Fair value range: low $91.3, high $140, with mid-point at $116.
Based on our latest analysis, CCEP looks meaningfully undervalued. The current price is $91.9 versus a composite fair-value midpoint of $116 (range $91.3–$140), which implies roughly 26.0% upside to the midpoint.
Our composite fair-value range for CCEP is $91.3–$140, with a midpoint of $116. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for CCEP's archetype.
Our current rating for CCEP is Strong Buy with a confidence score of 88/100. Strong Buy. The asset trades at an excessively pessimistic valuation despite durable local monopolies and highly visible $2B+ annual free cash flow. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for CCEP are: Elasticity Breakpoint; Franchisor Margin Extraction; Capital Intensity Spike. The single biggest risk is Elasticity Breakpoint: Consumers reject sustained price hikes, driving permanent volume declines and private label substitution.
Our current rating for CCEP is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($91.3–$140) versus the current price of $91.9.
CCEP is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for CCEP.